CRSP CRISPR Therapeutics AG

XNAS 51.47 Delayed
Find condors

Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

CRSP $51.47 —
Key stats
$51.47
52-Week Range
$44.12 – $67.73
YTD
-4.28%
IV Rank (30D)
45.55
Straddle Price
$6.75
P/C Vol Ratio
0.67
Market Cap
$4.7B
Open
$49.14
Day Range
$48.75 – $51.55
Volume
1,166,902
Prev Close
$49.01
Fair Value
MODEL: LONG

A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.

  • DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
  • Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
  • DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
  • P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
  • Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
  • Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
  • Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
  • Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
10-yr Treasury (rf)4.96%
Beta vs SPY1.26
Cost of Equity (CAPM)11.78% (VRP-adj)
WACC11.15%
Volatility Risk Premium+11.0pp (IV − HV30), ERP adj +40bps
Effective Tax Rate21.0%
Rev. Growth (YoY, DCF input)+30.0%
DCF Horizon10 years explicit + fade
Forward Tilt (NTM/TTM)×1.10 (applied to P/E, EV/EBITDA, P/S)
Free Cash Flow (TTM)$-0.4B
Return on Equity (TTM)-25.8%
Book / Price40.6% — banking bias active (P/B is primary)
Gross Margin (TTM)100.0%
FCF Margin (TTM)-9050.1%
Debt / Equity0.32
Quality Score3/6 — normal (10y DCF)
SMA 50$54.47 (Market Anchor value)
SMA 20 / Bollinger Mid$52.06
Bollinger Width / SMA2038.0% (drives anchor stability)
Net Debt$0.2B
Market Cap$4B
Peers used for multiples: AMGN, BIIB, EXEL, GILD, HALO, MRNA, NBIX, RGEN, RVMD, TECH (SIC-code peers; ETF co-membership was sector-incoherent)
60-Day Conviction
96%
20-Day Fair Value
≈ by Nov 25, 2026
$52.45
α +1.9% rank 86%
conviction
88%
40-Day Fair Value
≈ by Dec 24, 2026
$53.41
α +3.8% rank 88%
conviction
94%
60-Day Fair Value
≈ by Jan 22, 2027
$54.30
α +5.5% rank 84%
conviction
96%
MethodImplied PriceWeightDetail
DCF n/a 0%
DDM (Gordon) n/a 0%
Peer P/E n/a 0% median 34.5× · 7 peers
Peer EV/EBITDA n/a 0% median 18.3× · 8 peers
Peer P/B $204.09 22% median 10.2× · 10 peers
Peer P/S $0.33 22% median 6.6× · 9 peers
Market Anchor (SMA50) $54.47 0% stability 0% (BB-width)
Options Expected (B-L 30d) $48.32 56% 31 strikes · skew +0.17
As of 2026-10-27 · updated
About
Industry (SIC)
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) (2836) · industry map
Exchange
XNAS
Market Cap
$4.7B
Employees
393
List Date
2016-10-19
CIK
0001674416
Next Earnings
2026-11-09 (After-Close)
EPS Forecast
($1.06) (8 est.)
Headquarters
Zug
Homepage
https://www.crisprtx.com

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The…

Summary
—
composite
—
No summary data available for this symbol yet.

Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.

Chart
Seasonality
'21'22'23'24'25'26Avg
Jan4.87%-19.55%24.44%-4.71%0.39%-7.09%-0.27%
Feb-24.14%-6.35%-5.75%30.23%9.80%17.21%3.50%
Mar-6.45%9.28%-5.22%-18.61%-19.53%-21.72%-10.38%
Apr9.93%-24.99%8.08%-22.28%16.69%7.23%-0.89%
May-3.77%11.68%30.48%-0.13%-3.82%8.81%7.21%
Jun39.80%5.01%-12.99%-5.49%31.64%0.65%9.77%
Jul-22.74%17.57%1.92%6.19%15.98%-13.44%0.91%
Aug2.13%-12.05%-11.35%-13.00%-7.59%14.95%-4.49%
Sep-11.42%-0.38%-10.17%3.21%23.07%-2.64%0.28%
Oct-17.94%-17.05%-8.21%1.78%-3.28%-7.16%*-8.64%
Nov-16.30%5.32%52.53%0.81%-13.72%--5.73%
Dec0.66%-25.19%-8.81%-28.63%0.52%---12.29%
Total-46.81%-51.24%41.34%-48.27%45.00%-9.96%-11.66%
Technical Indicators

Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.

Trend Indicators
  • SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
  • EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
  • MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
  • ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
  • +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
  • RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
  • Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
  • Williams %R — inverted scale: <−80 oversold, >−20 overbought.

Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.

Volume & Volatility
  • Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
  • OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
  • Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
  • ATR / True Range — average daily $ move; sizing and stop-loss reference.
  • HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.

Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →

Trend Indicators

SMA 20: $51.83
SMA 50: $54.41
SMA 200: $52.92
Current: $51.47
EMA 12: $50.70
EMA 26: $51.97
MACD: -1.2715 | Signal: -0.0284
BEARISH
ADX (14): 12.44
RANGE
+DI: 19.79
−DI: 20.93

Momentum Oscillators

RSI (14): 48.23
NEUTRAL
Stoch %K: 33.10
Stoch %D: 23.96
Williams %R: -38.75

Volume & Volatility

BB Upper: $56.66
BB Lower: $47.00
NEUTRAL
OBV: 14,058,368
Vol SMA 20: 1,525,360
Vol ROC: -13.17%
ATR: $2.47
True Range: $2.80
HV 20: 48.8%
HV 30: 54.0%
HV 60: 53.7%

Data Summary

Data Points: 500
Last Updated:
Date Range: 2024-10-29T00:00:00 – 2026-10-27T00:00:00
AI Analysis

Here is the structured report for the given stock data:

Executive Summary

BULLISH (Confidence level: 6/10)

Key drivers: Bullish momentum signals from technical indicators, positive news sentiment, and high institutional interest.

Primary risks: High volatility, potential overbought conditions, and market corrections.

Investment thesis: CRISPR Therapeutics has strong fundamental support and a favorable catalyst-rich environment, which may drive the stock price higher. Recent positive news headlines have boosted investor confidence.

Recent news sentiment impact: Positive news sentiment has been driving the stock price higher, with a mix of neutral and positive headlines over the past week.

Technical Analysis

Trend Direction: Short-term (1-4 weeks): Bullish; Medium-term (1-3 months): Neutral/Bullish; Long-term (3-12 months): Bullish

Support/Resistance Levels: Key price levels from moving averages and technical patterns:

  • SMA 20: $56.55 (support)
  • SMA 50: $53.76 (resistance)
  • Upper Bollinger Band: $61.33 (resistance)

Momentum Signals:

  • RSI interpretation: Neutral (50.70) - no strong momentum signal
  • MACD signal: Bullish (1.19 / Signal: -0.35 / Histogram: 1.54)
  • Bollinger Bands position: Squeeze

Volume Analysis: Volume trends and institutional interest signals:

  • Volume SMA 20: 1424632.38
  • On-Balance Volume (OBV): 23838698.74
  • Volume Rate of Change: -63.54% ( bearish sentiment)

News & Sentiment Analysis

Recent Headlines Summary: Key themes from last 10 news articles:

  • 3 positive headlines (Zacks Investment Research, The Motley Fool) highlighting company's prospects and catalysts.
  • 1 neutral headline (Zacks Investment Research) discussing earnings report.
  • No negative headlines.

Sentiment Assessment: Aggregate news sentiment: POSITIVE

Catalyst Identification: Upcoming events:

  • Earnings reports
  • Product launches
  • Regulatory changes

Market Narrative: How news aligns with or contradicts technical signals:

  • Positive news headlines have reinforced the bullish momentum, while neutral headlines have not significantly impacted the market narrative.

Risk & Volatility Assessment

Beta Interpretation: Risk relative to market (beta >1.2 = high risk): 1.81 - High volatility

Volatility Regime: Current vs historical volatility levels: High volatility, with a recent increase in implied volatility.

Options Market Signals: IV rank, put/call ratios, unusual activity:

  • IV Rank: 26.5% (Medium) - shows if volatility is historically high/low
  • Current IV: 65.4%
  • Expected Move: $7.22 (28 DTE), 7-DTE: $3.20

Downside Protection: Support levels and risk management considerations:

  • SMA 50: $53.76 (support)
  • Lower Bollinger Band: $51.78 (support)

Market Context & Positioning

Sector Performance: Relative strength vs sector/market:

  • CRISPR Therapeutics is outperforming the biotech sector.

Institutional Activity: Volume patterns suggesting institutional interest:

  • High volume on recent buy signals

Correlation Analysis: How stock moves relative to market (R-squared interpretation):

  • Correlation: 0.39 - a moderate positive correlation between CRISPR Therapeutics and the broader market.

Relative Valuation: Position within trading range:

  • The stock is currently trading near its upper Bollinger Band, suggesting a potentially overbought condition.

Key Levels & Action Items

Critical Price Levels: Support/resistance to monitor:

  • SMA 20: $56.55 (support)
  • SMA 50: $53.76 (resistance)
  • Upper Bollinger Band: $61.33 (resistance)

Breakout/Breakdown Levels: Technical levels that could trigger significant moves:

  • Lower Bollinger Band: $51.78 (breakdown risk)
  • SMA 200: $53.24 (support)

Time-Sensitive Catalysts: Earnings dates, FDA approvals, product launches:

  • Upcoming earnings reports and potential catalysts may drive the stock price higher.

Risk Management: Stop-loss levels and position sizing considerations:

  • Consider setting a stop-loss at the SMA 50 level ($53.76) to limit potential losses in case of a market correction.
  • Monitor volume patterns for signs of institutional interest or selling pressure.
Generated
News
All CRSP news →
Earnings History
15 of 23 under expected move
Avg Expected Move
6.65%
Avg Actual Move
5.53%
Each row pairs the pre-earnings straddle-implied expected move with the realized close-to-close move. Sorted oldest first.
Earnings Date Timing Expected Move Actual Move Ratio Outcome
2021-02-16 After-Close 4.89% 3.41% 0.70x Within
2021-04-27 After-Close 4.89% 1.88% 0.38x Within
2021-07-29 After-Close 5.49% 1.70% 0.31x Within
2021-11-03 After-Close 5.26% 4.00% 0.76x Within
2022-02-15 After-Close 6.81% 1.64% 0.24x Within
2022-05-09 After-Close 13.56% 9.44% 0.70x Within
2022-08-08 After-Close 5.15% 7.69% 1.49x Exceeded
2022-11-01 After-Close 6.92% 5.11% 0.74x Within
2023-02-21 After-Close 6.30% 8.04% 1.28x Exceeded
2023-05-08 After-Close 6.36% 13.33% 2.10x Exceeded
2023-08-07 After-Close 6.43% 9.74% 1.51x Exceeded
2023-11-06 After-Close 8.07% 13.57% 1.68x Exceeded
2024-02-21 After-Close 5.24% 4.59% 0.88x Within
2024-05-08 After-Close 6.87% 0.49% 0.07x Within
2024-08-05 After-Close 9.72% 0.66% 0.07x Within
2024-11-05 After-Close 6.65% 0.71% 0.11x Within
2025-02-11 After-Close 4.42% 9.29% 2.10x Exceeded
2025-05-06 After-Close 7.69% 3.29% 0.43x Within
2025-08-04 After-Close 7.17% 6.71% 0.94x Within
2025-11-10 After-Close 6.46% 1.15% 0.18x Within
2026-02-12 After-Close 4.75% 8.46% 1.78x Exceeded
2026-05-05 After-Close 4.58% 5.15% 1.12x Exceeded
2026-08-03 After-Close 9.28% 7.06% 0.76x Within

Earnings calendar: this week’s reports with expected vs actual moves →

CRSP Options Activity & IV Rank

CRSP IV rank history, 52-week IV rank and IV percentile →

Volatility Metrics

Current IV: 58.5%
7-DTE IV: 60.4%
Expected Move: $6.75
7-DTE Move: $4.10
Days to Exp: 31 (2026-11-27)

Options Flow

Call Volume: 151
Put Volume: 101
P/C Volume: 0.669
BULLISH
Call OI: 200
Put OI: 120
P/C OI: 0.6
Total OI: 320

ATM Options Pricing

ATM Call: $3.05
ATM Put: $3.70
Call %: 5.9%
Put %: 7.2%

Chain Summary

Chain Volume: 4,308
Chain OI: 58,702
Last Updated: 10/27/2026
Spread Scanner GPU
Full Algorithm Docs ↗

Each spread is ranked by a composite score built in three stages. Full documentation →

Stage 1 — Base Score (GPU scanner)

score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.

Stage 2 — Skew Adjustment (±25% cap)

RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.

Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
  • RSI <40 bullish / >60 bearish
  • MACD crossover + histogram trend
  • Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
  • Stochastic %K <20 / >80
  • Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
  • Blended ATR + straddle expected-move penalty
  • Bollinger Band signal (+ counter-trend penalty)
  • BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
  • IV rank ≥ 75 → strong boost for credit spreads
  • IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
  • Min open interest across all legs
  • OI < 100 → −0.10 · OI < 500 → −0.05

score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →

Enter a ticker to scan for optimal spread opportunities.

Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.

Dealer Positioning
TYPICAL γ

Estimated net dealer gamma is at the 33rd percentile of this name's own daily history, within its typical range. This describes current positioning; it is not a forecast or a trading signal.

Gamma percentile
33%
vs own history
GEX tilt
-0.09
OI-weighted, today
Vanna tilt
+0.18
δ-sensitivity to IV
Charm tilt
-0.57
δ-decay vs time
Charm tilt -0.57: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.

Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.

Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.

Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.

This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.

· 94 ATM contracts, 18k total OI
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Metric:
Wing vs ATM
IV(put wing) − IV(ATM), in vol points

How much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.

  • Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
  • Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
  • Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
  • Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each side

Which side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.

  • Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
  • Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
  • Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
  • Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together

Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:

  • High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
  • Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
  • Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d —
— pts EXTREME
ATM 60.6% / Wing —
30 DTE / 10d —
— pts EXTREME
ATM 56.4% / Wing —

Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.

Volatility Surface

Enter a ticker to render the implied volatility surface.

Volatility Smile

Enter a ticker to render the implied volatility smile.

IV Rank (7 DTE)43.3MediumOct 27
IV Rank (30 DTE)45.5MediumOct 27
Straddle Price (30 DTE)$6.75Oct 27
Beta Analysis

Risk Metrics

Beta: 1.8703
Alpha: -31.49%
Correlation: 0.4132
R-Squared: 17.1%
Stock Volatility: 57.5%
Market Volatility: 12.7%

Analysis Details

Benchmark: SPY
Data Points: 251
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
Beta & Alpha Over Time
Notable investors who own CRSP
3 of 37 tracked investors
InvestorValueShare of their portfolioRankQ/Q sharesSource
Citadel Hedge fund
Ken Griffin
$25.4M
0.01%
#1017 of 6285-9.8%13F
Millennium Management Hedge fund
Izzy Englander
$20.8M
0.01%
#1101 of 3716+1.3%13F
Rockefeller Capital Management Family office
Rockefeller family
$5.5M
0.01%
#931 of 4729+38.6%13F

Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions

CRSP Institutional Ownership (13F)

Latest filings — 2026-09-30
Diluted shares outstanding: 91,087,841 (as of 2026-03-31)

Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.

  • Shares — long equity positions in this name, aggregated across share classes.
  • Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
  • % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
  • Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.

Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.

534 filers157,590,142 shares$8.59B value173.01% of float
# Filer Shares Value % of Total % of Float Period
1 ARK Investment Management LLC 18,921,878 $1.03B 12.02% 20.77% 2026-06-30
2 BlackRock, Inc. Custodian 16,697,954 $910.71M 10.61% 18.33% 2026-06-30
3 Orbis Allan Gray Ltd 10,898,322 $594.39M 6.92% 11.96% 2026-06-30
4 Capital World Investors 9,499,050 $518.08M 6.03% 10.43% 2026-06-30
5 State Street Corp 8,643,332 $471.41M 5.49% 9.49% 2026-06-30
6 GSK plc 6,441,254 $351.31M 4.09% 7.07% 2026-06-30
7 Geode Capital Management, LLC Custodian 5,019,830 $273.84M 3.19% 5.51% 2026-06-30
8 Vanguard Group Inc Custodian 4,536,788 $237.91M 2.77% 4.98% 2025-12-31
9 T. Rowe Price Investment Management, Inc. 4,106,034 $223.94M 2.61% 4.51% 2026-06-30
10 SR One Capital Management, LP 4,077,526 $222.39M 2.59% 4.48% 2026-06-30
11 Two Sigma Investments, LP Custodian 3,977,242 $216.92M 2.53% 4.37% 2026-06-30
12 FMR LLC Custodian 3,817,006 $208.18M 2.42% 4.19% 2026-06-30
13 Sumitomo Mitsui Trust Group, Inc. 3,441,468 $187.70M 2.19% 3.78% 2026-06-30
14 Amova Asset Management Americas, Inc. 3,440,194 $187.52M 2.18% 3.78% 2026-06-30
15 EcoR1 Capital, LLC 2,778,552 $151.54M 1.77% 3.05% 2026-06-30
16 UBS Group AG Custodian 2,634,998 $143.71M 1.67% 2.89% 2026-06-30
17 Capital International Investors 2,536,814 $138.36M 1.61% 2.79% 2026-06-30
18 Vanguard Capital Management LLC 2,363,694 $128.92M 1.50% 2.60% 2026-06-30
19 Bank of America Corp Custodian 2,310,210 $126.00M 1.47% 2.54% 2026-06-30
20 NEA Management Company, LLC 2,117,140 $115.47M 1.34% 2.32% 2026-06-30
21 Charles Schwab Investment Management, Inc. 2,115,674 $115.39M 1.34% 2.32% 2026-06-30
22 D. E. Shaw & Co., Inc. Custodian 1,787,624 $97.50M 1.14% 1.96% 2026-06-30
23 Morgan Stanley Custodian 1,759,898 $95.98M 1.12% 1.93% 2026-06-30
24 Northern Trust Corp Custodian 1,726,182 $94.15M 1.10% 1.90% 2026-06-30
25 Vanguard Portfolio Management LLC 1,297,426 $70.76M 0.82% 1.42% 2026-06-30
21 filers$168.41M notional
# Filer Notional Value % of Total Period
1 Susquehanna International Group, LLP Custodian $35.53M 21.10% 2026-06-30
2 Citadel Advisors LLC Custodian $27.95M 16.59% 2026-06-30
3 Jane Street Group, LLC Custodian $25.13M 14.92% 2026-06-30
4 IMC-Chicago, LLC Custodian $16.68M 9.90% 2026-06-30
5 D. E. Shaw & Co., Inc. Custodian $11.80M 7.01% 2026-06-30
6 PEAK6 LLC $7.67M 4.55% 2026-06-30
7 Millennium Management LLC Custodian $6.29M 3.74% 2026-06-30
8 Walleye Trading LLC $6.01M 3.57% 2026-06-30
9 Caption Management, LLC $6.00M 3.56% 2026-06-30
10 Citigroup Inc. Custodian $5.56M 3.30% 2026-06-30
11 Cubist Systematic Strategies, LLC $4.24M 2.52% 2025-09-30
12 Point72 Asset Management, L.P. $2.78M 1.65% 2026-06-30
13 GROUP ONE TRADING LLC Custodian $2.49M 1.48% 2026-06-30
14 TUDOR INVESTMENT CORP ET AL $2.48M 1.47% 2026-06-30
15 Simplex Trading, LLC Custodian $2.12M 1.26% 2026-06-30
16 Walleye Capital LLC $2.01M 1.19% 2026-06-30
17 NOMURA HOLDINGS INC $1.96M 1.17% 2026-06-30
18 HUB Investment Partners, LLC $970.81K 0.58% 2026-06-30
19 Squarepoint Ops LLC $458.14K 0.27% 2026-06-30
20 UBS Group AG Custodian $272.70K 0.16% 2026-06-30
21 Arkadios Wealth Advisors $21.82K 0.01% 2026-06-30
19 filers$169.51M notional
# Filer Notional Value % of Total Period
1 Susquehanna International Group, LLP Custodian $36.91M 21.78% 2026-06-30
2 Citadel Advisors LLC Custodian $31.64M 18.67% 2026-06-30
3 PEAK6 LLC $23.27M 13.73% 2026-06-30
4 IMC-Chicago, LLC Custodian $13.84M 8.17% 2026-06-30
5 SFE Investment Counsel $12.46M 7.35% 2026-06-30
6 Jane Street Group, LLC Custodian $11.70M 6.90% 2026-06-30
7 Walleye Trading LLC $7.06M 4.16% 2026-06-30
8 GROUP ONE TRADING LLC Custodian $6.56M 3.87% 2026-06-30
9 Citigroup Inc. Custodian $5.56M 3.28% 2026-06-30
10 WOLVERINE ASSET MANAGEMENT LLC $5.45M 3.22% 2026-06-30
11 Jain Global LLC $2.37M 1.40% 2026-06-30
12 Simplex Trading, LLC Custodian $1.97M 1.16% 2026-06-30
13 NOMURA HOLDINGS INC $1.96M 1.16% 2026-06-30
14 Point72 Asset Management, L.P. $1.92M 1.13% 2026-06-30
15 TUDOR INVESTMENT CORP ET AL $1.75M 1.03% 2026-06-30
16 Caption Management, LLC $1.64M 0.97% 2026-06-30
17 Cubist Systematic Strategies, LLC $1.45M 0.86% 2025-09-30
18 Walleye Capital LLC $1.33M 0.79% 2026-06-30
19 D. E. Shaw & Co., Inc. Custodian $665.39K 0.39% 2026-06-30

CRSP Insider Trading (Form 4)

Latest: 2026-10-21
Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
Filed Reporter Role Action Shares Avg Price Net $ Link
2026-10-21 Andrew Jacob Silver Chief Financial Officer Grant (A) +25,000 RSU — EDGAR
2026-10-20 Samarth Kulkarni Chief Executive Officer Mixed +52,163 $49.78 -$2.38M EDGAR
2026-10-16 Simeon George Director Mixed +15,486 $25.62 -$300.4K EDGAR
2026-10-15 Samarth Kulkarni Chief Executive Officer Mixed +4,235 $49.26 -$201.9K EDGAR
2026-10-15 James R. Kasinger General Counsel and Secretary Mixed +1,073 $49.26 -$51.2K EDGAR
2026-10-08 James R. Kasinger General Counsel and Secretary Mixed — $36.83 -$92.4K EDGAR
2026-09-24 James R. Kasinger General Counsel and Secretary Mixed — $36.93 -$484.8K EDGAR
2026-09-21 Ali Behbahani Director Other (J) +75 — EDGAR
2026-09-21 Ali Behbahani Director Mixed +16,321 $27.49 -$360.9K EDGAR
2026-08-11 Raju Prasad Chief Financial Officer Gift (G) −750 — EDGAR
2026-06-09 Simeon George Director Grant (A) +13,000 opt — EDGAR
2026-06-09 Sandesh Mahatme Director Grant (A) +13,000 opt — EDGAR
2026-06-09 Maria Fardis Director Grant (A) +13,000 opt — EDGAR
2026-06-09 Christian Rommel Director Grant (A) +13,000 opt — EDGAR
2026-06-09 Katherine A High Director Grant (A) +13,000 opt — EDGAR
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.

CRSP Insider Holdings

9 insiders · @ $51.47
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
# Insider Role Shares Disclosed Exposure Lifetime OM Net Filings Last Filed
1 Samarth Kulkarni Chief Executive Officer 445,358 $22.92M -$66.60M 89 2026-10-20
2 James R. Kasinger General Counsel and Secretary 95,857 $4.93M -$8.51M 41 2026-10-15
3 Simeon George Director 85,173 $4.38M $50.78M 12 2026-10-16
4 Douglas A Treco Director 22,000 $1.13M $1.14M 8 2026-06-09
5 Naimish Patel Chief Medical Officer 19,357 $996.3K -$454.2K 11 2026-06-02
6 Julianne Bruno Chief Operating Officer 19,346 $995.7K -$336.1K 7 2025-03-24
7 Ali Behbahani Director 16,666 $857.8K -$780.9K 13 2026-09-21
8 Raju Prasad Chief Financial Officer 14,815 $762.5K -$5.60M 16 2026-08-11
9 John Greene Director 7,000 $360.3K $313.9K 9 2026-06-09
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.

CRSP Board & Officers

As of SEC filings through Oct 21, 2026

Directors 11

Officers 4

Changes in the last 10 years (36)
Oct 19, 2026The company announced the departure of Raju Prasad as Chief Financial Officer in an SEC filing
Oct 19, 2026Andrew Jacob Silver became Chief Financial Officer
Jun 5, 2025Briggs Morrison became a director
Mar 24, 2025The company announced the departure of Julianne Bruno as Chief Operating Officer in an SEC filing
May 30, 2024Sandesh Mahatme became a director
May 30, 2024Christian Rommel became a director
May 28, 2024Naimish Patel became Chief Medical Officer
May 23, 2024Julianne Bruno became Chief Operating Officer
Dec 14, 2023The company announced the departure of Phuong Khanh Morrow as Chief Medical Officer in an SEC filing
Mar 28, 2023The company announced the departure of Bradley J PhD Bolzon from the board in an SEC filing
Mar 14, 2023Raju Prasad became Chief Financial Officer
Mar 9, 2023The company announced the departure of Brendan Smith as Chief Financial Officer in an SEC filing
Oct 27, 2022The company announced the departure of Lawrence Otto Klein as Cbo & COO in an SEC filing
Jun 9, 2022Maria Fardis became a director
May 23, 2022Phuong Khanh Morrow became Chief Medical Officer
Dec 14, 2021The company announced the departure of Tony W Ho as Executive VP, Head of R&D in an SEC filing
Oct 14, 2021Brendan Smith became Chief Financial Officer
Jun 10, 2021Harold Edward Fleming became a director
Jun 11, 2020Douglas A Treco became a director
Mar 12, 2020Lawrence Otto Klein listed as Cbo & COO (previously Chief Business Officer) in SEC filings
Not reported recently (22)
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.

CRSP Proposed Insider Sales (Form 144)

Latest: 2026-10-14
Last 30d: 2 filings · $840K notice value  ·  Last 90d: 4 filings · $2.2M notice value · 3 unique filers · 50% under 10b5-1 plans

What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.

How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.

10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.

"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.

Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.

Top 90-day filers: ALI BEHBAHANI (1, $781K) · JAMES KASINGER (2, $746K) · SIMEON GEORGE (1, $720K)
Filed Filer Role Shares Notice Value Planned Sale Broker Plan Link
2026-10-14 SIMEON GEORGE Director 14,514 $720.4K 2026-10-14 Morgan Stanley Smith Barney LLC … — EDGAR
2026-10-06 JAMES KASINGER Officer 1,990 $119.5K 2026-10-06 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
2026-09-22 JAMES KASINGER Officer 10,400 $626.5K 2026-09-22 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
2026-09-17 ALI BEHBAHANI Director 13,679 $780.9K 2026-09-17 Morgan Stanley Smith Barney LLC … — EDGAR
2026-01-22 Samarth Kulkarni Officer 60,000 $3.65M 2026-01-22 Goldman Sachs & Co. LLC 10b5-1 EDGAR
2026-01-22 RAJU PRASAD Officer 34,972 $2.11M 2026-01-22 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
2026-01-20 Samarth Kulkarni Officer 30,000 $1.58M 2026-01-20 Goldman Sachs & Co. LLC 10b5-1 EDGAR
2026-01-06 RAJU PRASAD Officer 29,700 $1.79M 2026-01-06 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
2025-12-22 RAJU PRASAD Officer 10,000 $559.5K 2025-12-22 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
2025-02-18 Samarth Kulkarni Officer 45,000 $2.35M 2025-02-18 Goldman Sachs & Co. LLC 10b5-1 EDGAR
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
ETF Holders
56 ETFs hold CRSP
25 shown · $475.92M total exposure · 0.13% AUM-weighted avg weight
# ETF Provider Weight $ Exposure ETF AUM As Of
1 XBI State Street® SPDR® S&P® Biotech ETF SPDR (State Street) 1.37% $142.3M $10.4B 2026-10-23
2 IWM iShares Russell 2000 ETF iShares (BlackRock) 0.15% $111.4M $74.6B 2026-10-23
3 VXF Vanguard Extended Market ETF Vanguard 0.06% $60.5M — 2026-09-30
4 IWN iShares Russell 2000 Value ETF iShares (BlackRock) 0.26% $35.7M $13.9B 2026-10-23
5 IBB iShares Biotechnology ETF iShares (BlackRock) 0.32% $33.7M $10.7B 2026-10-23
6 VTWO Vanguard Russell 2000 ETF Vanguard 0.16% $28.9M — 2026-09-30
7 AVSC Avantis U.S. Small Cap Equity ETF Avantis 0.24% $7.6M $3.2B 2026-10-23
8 ITOT iShares Core S&P Total U.S. Stock Market ETF iShares (BlackRock) 0.01% $6.4M $96.5B 2026-10-23
9 LABU Direxion Daily S&P Biotech Bull 3X ETF Direxion 0.96% $5.5M — 2026-10-26
10 IWO iShares Russell 2000 Growth ETF iShares (BlackRock) 0.04% $5.5M $13.7B 2026-10-23
11 FESM Fidelity Enhanced Small Cap Core ETF Fidelity 0.07% $4.4M $6.6B 2026-10-23
12 VT Vanguard Total World Stock ETF Vanguard 0.00% $4.3M — 2026-09-30
13 IDNA iShares Genomics Immunology and Healthcare ETF iShares (BlackRock) 1.28% $4.1M $321.2M 2026-10-23
14 VTWV Vanguard Russell 2000 Value ETF Vanguard 0.29% $4.0M — 2026-09-30
15 SMLF iShares U.S. Small-Cap Equity Factor ETF iShares (BlackRock) 0.08% $3.5M $4.2B 2026-10-23
16 GNOM Global X Genomics & Biotechnology ETF Global X 2.50% $2.7M — 2026-10-26
17 KOMP State Street® SPDR® S&P Kensho New Economies Composite ETF SPDR (State Street) 0.10% $2.4M $2.5B 2026-10-23
18 RSSL Global X Russell 2000 ETF Global X 0.15% $2.1M — 2026-10-26
19 FHLC Fidelity MSCI Health Care Index ETF Fidelity 0.06% $2.1M $3.8B 2026-10-23
20 ESML iShares ESG Aware MSCI USA Small-Cap ETF iShares (BlackRock) 0.06% $1.7M $2.7B 2026-10-23
21 NXTE AXS Green Alpha ETF Nport 2.81% $1.6M — 2026-06-30
22 JHSC John Hancock Multifactor Small Cap ETF Nport 0.21% $1.4M — 2026-06-30
23 BBSC JPMorgan BetaBuilders U.S. Small Cap Equity ETF JPMorgan 0.19% $1.4M $734.0M 2026-10-26
24 ONEQ Fidelity Nasdaq Composite Index ETF Fidelity 0.01% $1.4M $10.7B 2026-10-23
25 IWV iShares Russell 3000 ETF iShares (BlackRock) 0.01% $1.3M $20.4B 2026-10-23
Fundamentals

Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.

Metrics
  • Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
  • Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
  • Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
  • Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
  • Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
  • YoY growth — compare to the same quarter a year earlier to remove seasonality.
  • Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
  • Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.

TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.

Trailing P/E
—
TTM Diluted EPS
$-6.20
TTM Revenue
$4.10M
TTM Net Income
$-568.53M
TTM Op. Cash Flow
$-399.96M
Quarterly figures (12 quarters)
QuarterPeriod EndRevenueNet IncomeDiluted EPSOp. Cash Flow
Q1 '262026-03-31$1.46M$-122.93M$-1.28$-108.90M
Q4 '252025-12-31$864.00K$-130.61M$-1.35$-92.55M
Q3 '252025-09-30$889.00K$-106.44M$-1.17$-84.63M
Q2 '252025-06-30$892.00K$-208.55M$-2.40$-113.88M
Q1 '252025-03-31$865.00K$-136.00M$-1.58$-53.95M
Q4 '242024-12-31$35.69M$-37.31M$-0.42$-50.03M
Q3 '242024-09-30$602.00K$-85.94M$-1.01$-106.91M
Q2 '242024-06-30$517.00K$-126.41M$-1.49$-95.58M
Q1 '242024-03-31$504.00K$-116.59M$-1.43$109.75M
Q4 '232023-12-31$201.21M$89.35M$1.13$-93.57M
Q3 '232023-09-30—$-112.15M$-1.41$-40.86M
Q2 '232023-06-30$70.00M$-77.74M$-0.98$-134.75M
Q1 2026 • period ending 2026-03-31 • filed 2026-05-04
Valuation

Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.

Price Multiples
  • P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
  • P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
  • P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
  • EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
  • EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
  • ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
  • ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
  • Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
  • FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
  • Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
  • Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
  • Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
  • Multiples expanding while earnings are flat = sentiment-driven rally.
  • Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
2.58
P/S
1142.65
EV/EBITDA
—
EV/Sales
1182.17
ROE
-31.3%
ROA
-20.9%
Div Yield
0.00%
FCF Yield
-8.53%
Debt/Equity
0.32
Current Ratio
—
Market Cap
$4.69B
as of 2026-10-27
Short Interest & Float

Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.

Metric definitions
  • Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
  • SI % of Float — short interest / free float. The key crowding metric.
  • Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
  • Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
  • Free Float — shares available for public trading (total shares minus insider / restricted).
  • Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
  • SI % of Float < 5% — typical, no particular signal.
  • 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
  • 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
  • >30% — extreme; borrow is likely expensive and squeeze risk is material.
  • Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
  • Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
  • A sudden drop in SI after a rally may indicate a squeeze in progress.

Short interest is reported mid-month and end-of-month; short volume is daily.

Short Interest
18.68M
SI % of Float
23.82%
Days to Cover
9.58
Short Vol Ratio
48.3%
Free Float
78.42M
Float %
81.1%
Short interest 2026-09-30 • Short volume 2026-10-27 • Float 2026-09-22